Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR
Our study reveals a novel mechanism by which the NOTCH2-NTRK1 fusion confers resistance to osimertinib through its interaction with EGFR in NSCLC.
Authors
- Anjia Han (ORCID: https://orcid.org/0000-0003-3357-5348)
- Jiecheng Ye
- Fenfen Zhang
- Huabin Gao
- Huiting Wei
- Huicong Liu (ORCID: https://orcid.org/0000-0003-3651-9114)
- Hui Li (ORCID: https://orcid.org/0000-0001-8365-7670)
- Huijuan Shi (ORCID: https://orcid.org/0000-0002-5325-9732)
- Jiangtao Liang (ORCID: https://orcid.org/0000-0002-3530-6347)
- Shuai Zheng (ORCID: https://orcid.org/0000-0002-5308-8304)
- Gengpeng Lin
- Tiantian Zhen (ORCID: https://orcid.org/0000-0003-3320-714X)
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1016/j.tranon.2025.102577
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00